International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Apr 2005
Initial clinical experience with frameless radiosurgery for patients with intracranial metastases.
To review the initial clinical experience with frameless stereotactic radiosurgery (SRS) for treating intracranial metastatic disease. ⋯ Frameless optically guided radiosurgery is less invasive, can be performed as a standard radiotherapy-based simulation procedure, and maintains submillimetric accuracy. Our initial results with frameless SRS for metastatic disease suggest survival times and local control (88%) eqiuvalent to frame-based methodologies. Practical noninvasive delivery makes treatment and potential retreatment to avoid WBRT more feasible.
-
Int. J. Radiat. Oncol. Biol. Phys. · Apr 2005
Treatment of bone metastases with palliative radiotherapy: patients' treatment preferences.
To determine the proportion of patients undergoing palliative radiotherapy (RT) for bone pain who would like to participate in the decision-making process, and to determine their choice of palliative RT regimen (2000 cGy in five fractions vs. 800 cGy in one fraction) for painful bone metastases. ⋯ Most participating patients preferred to decide either by themselves or with the radiation oncologists which treatment option they preferred. An 800-cGy-in-one-fraction regimen was favored, independent of the treated site. The convenience of the treatment plan and the likelihood of bone fracture were the most important factors influencing patients' choice.
-
Int. J. Radiat. Oncol. Biol. Phys. · Apr 2005
ReviewHigh-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
To present the long-term outcome and morbidity of high-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy (EBRT) for localized prostate cancer. ⋯ Our 10-year results have demonstrated HDR-BT plus EBRT is a proven treatment for all stages of localized prostate cancer. The morbidity was low, but post-RT transurethral resection should be avoided.
-
Int. J. Radiat. Oncol. Biol. Phys. · Apr 2005
Clinical TrialReirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.
Inoperable locoregional recurrences of head-and-neck cancer in a previously irradiated volume represent a therapeutic dilemma. Chemotherapy alone has no curative potential, whereas reirradiation and concurrent chemoradiation can salvage a small fraction of patients. Mucosal toxicity of concurrent chemoradiation requires substantial dose reduction of chemotherapy. Alternating chemoradiation offers the chance to give both full-dose chemotherapy and radiotherapy. The latter may provide a particular advantage for recurrent, potentially radiation resistant tumors. The feasibility and efficacy of a full-dose docetaxel containing alternating chemoradiation schedule was tested. ⋯ Alternating chemoreirradiation in recurrences of head-and-neck cancer resulted in 80% overall response with acceptable toxicity. A significant minority of patients had durable tumor control with a chance of long-term survival.
-
Int. J. Radiat. Oncol. Biol. Phys. · Apr 2005
The effect of finite patient dimensions and tissue inhomogeneities on dosimetry planning of 192Ir HDR breast brachytherapy: a Monte Carlo dose verification study.
To evaluate the accuracy of clinical dosimetry planning using commercially available treatment planning systems in (192)Ir high-dose-rate (HDR) breast brachytherapy, with emphasis on skin dose, in view of potential uncertainties owing to the patient finite dimensions and the presence of the lung. ⋯ Dose-volume histogram and all other relevant planning quality indices for the planning target volume calculated by the treatment planning system are credible. Skin and lung dose calculations by the treatment planning system can be thought of as a conservative approach in view of the reported dose overestimation.